Monoclonal antibodies interfering with the signalling of the hepatocyte growth factor receptor encoded by the MET oncogene and of the epidermal growth factor receptor (EGFR) encoded by the HER1 gene have received approval for the treatment of various types of cancers. This evidence concerns the gene EGFR and cancer.